DK1001752T3 - Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler - Google Patents

Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler

Info

Publication number
DK1001752T3
DK1001752T3 DK98929022T DK98929022T DK1001752T3 DK 1001752 T3 DK1001752 T3 DK 1001752T3 DK 98929022 T DK98929022 T DK 98929022T DK 98929022 T DK98929022 T DK 98929022T DK 1001752 T3 DK1001752 T3 DK 1001752T3
Authority
DK
Denmark
Prior art keywords
dismutation
superoxide radicals
synthetic catalysts
analgesic methods
analgesic
Prior art date
Application number
DK98929022T
Other languages
Danish (da)
English (en)
Inventor
Daniela Salvemini
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK1001752T3 publication Critical patent/DK1001752T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
DK98929022T 1997-06-20 1998-06-15 Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler DK1001752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20
PCT/US1998/012231 WO1998058636A1 (en) 1997-06-20 1998-06-15 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Publications (1)

Publication Number Publication Date
DK1001752T3 true DK1001752T3 (da) 2004-04-19

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98929022T DK1001752T3 (da) 1997-06-20 1998-06-15 Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler

Country Status (12)

Country Link
US (2) US6180620B1 (xx)
EP (1) EP1001752B1 (xx)
JP (1) JP2002506445A (xx)
AT (1) ATE256467T1 (xx)
AU (1) AU733415B2 (xx)
CA (1) CA2294155A1 (xx)
DE (1) DE69820633T2 (xx)
DK (1) DK1001752T3 (xx)
ES (1) ES2215305T3 (xx)
PT (1) PT1001752E (xx)
WO (1) WO1998058636A1 (xx)
ZA (1) ZA985376B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
AU737650B2 (en) 1997-11-03 2001-08-23 Duke University Substituted porphyrins
ATE552260T1 (de) * 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
ES2240101T3 (es) 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
US20050175580A1 (en) * 2001-01-05 2005-08-11 Daniela Salvemini Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
AU2002248366B2 (en) * 2001-01-19 2006-10-26 Aeolus Sciences, Inc. Cancer therapy
WO2002058686A2 (en) * 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
JP4369124B2 (ja) * 2001-03-02 2009-11-18 メタファー・ファーマシューティカルズ・インコーポレイテッド 金属錯体のクロマトグラフィー
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
EP1417219A4 (en) * 2001-06-08 2005-05-25 Metaphore Pharmaceuticals Inc LIBRARIES OF PEPTIDES, CHIRAL AZACROWNS AND PEPTIDOMIMETICS WITH CONFORMATIONAL CONSTRAINTS AND METHODS OF MAKING THE SAME
CA2451602A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease
WO2003039561A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
JP2005513063A (ja) * 2001-12-14 2005-05-12 アルコン，インコーポレイティド 眼の障害および疾患の治療用スーパーオキシドジスムターゼ模擬体
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
CA2488500A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
US6984636B2 (en) * 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
WO2004026262A2 (en) * 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
BR0317026A (pt) * 2002-12-06 2005-10-25 Alcon Inc Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
JP2007513948A (ja) * 2003-12-11 2007-05-31 アルコン，インコーポレイテッド 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006069326A2 (en) * 2004-12-21 2006-06-29 Metaphore Pharmaceuticals, Inc. Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
EP3527079A1 (en) 2006-10-12 2019-08-21 Galera Labs, LLC Methods of treating oral mucositis
WO2009065059A2 (en) * 2007-11-14 2009-05-22 Kereos, Inc. Super-oxide dismutase mimetics
WO2009143454A2 (en) 2008-05-22 2009-11-26 Kereos, Inc. Combination antitumor therapy
RU2506083C2 (ru) 2008-05-23 2014-02-10 Нэшнл Джуиш Хелт Способ лечения поражений, ассоциированных с воздействием алкилирующих веществ
WO2013048965A1 (en) * 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
MX2018001605A (es) * 2015-08-11 2018-09-26 Galera Labs Llc Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral.
CN110520107A (zh) 2017-02-15 2019-11-29 加莱拉实验室有限责任公司 用于局部肠递送的五氮杂大环状环配合物
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
KR20200118823A (ko) 2018-01-31 2020-10-16 갈레라 랩스, 엘엘씨 펜타아자 마크로시클릭 고리 복합체 및 백금-기재 항암제를 사용한 조합 암 요법
AU2021220207A1 (en) 2020-02-13 2022-09-01 Teva Pharmaceuticals International Gmbh Solid state forms of Avasopasem manganese and process for preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
ES2113952T3 (es) 1991-07-19 1998-05-16 Monsanto Co Complejos de manganeso con ligandos macrociclicos nitrogenados eficaces como catalizadores para dismutar superoxidos.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1225631A (zh) 1996-03-13 1999-08-11 孟山都公司 有歧化过氧化物催化剂效果的含氮大环配位体锰或铁配合物的生物缀合物

Also Published As

Publication number Publication date
PT1001752E (pt) 2004-05-31
US6180620B1 (en) 2001-01-30
AU733415B2 (en) 2001-05-17
ES2215305T3 (es) 2004-10-01
ZA985376B (en) 1999-06-21
US6395725B1 (en) 2002-05-28
JP2002506445A (ja) 2002-02-26
ATE256467T1 (de) 2004-01-15
AU8068598A (en) 1999-01-04
EP1001752A1 (en) 2000-05-24
WO1998058636A1 (en) 1998-12-30
EP1001752B1 (en) 2003-12-17
CA2294155A1 (en) 1998-12-30
DE69820633D1 (de) 2004-01-29
DE69820633T2 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
DK1001752T3 (da) Analgetiske fremgangsmåder under anvendelse af syntetiske katalysatorer til dismutation af superoxidradikaler
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
DE60010098D1 (de) 28-epirapaloge
DK0928362T3 (da) Blokerende sammensætning til anvendelse i en underjordisk formation
ATA199196A (de) Kraftstoff-verteilerrohr
EE9700113A (et) Madala molekulmassiga bitsüklilised trombiini inhibiitorid
ES2146774T3 (es) Polimeros de ioneno que contienen aniones biologicamente activos.
TR199901022T2 (xx) Kolostrinin ve kullan�mlar�
DE50013384D1 (de) Hochdruckeinspritzsystem mit Common Rail
PT925319E (pt) Polimeros de triazina e sua utilizacao em dispositivos electroluminescentes
NO983945L (no) Isokinoliner som er nyttige som analgetika
BR9711420A (pt) Injetor sem agulha
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
FI990842A (fi) Sovitelma kosketinkiskon yhteydessä
DE60039679D1 (de) Reduktion des molekulargewichts von olefincopolymerisaten
AR028772A1 (es) 5-aminoalquil-pirazol[4,3-d] pirimidinas
DE59910842D1 (de) Brennstoffeinspritzvorrichtung
NO20005578D0 (no) Arrangement for Õ redusere eksplosjonspotensialet i forankrede fortøyningssvivler til et minimum
ES1044257Y (es) Dispositivo de seguridad para montaje de aisladores en carriles/guia portadores de planchas aislantes, falsos techos y/o similares.
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
ATE304213T1 (de) Schaltmatte als sicherheitsvorrichtung
SG90720A1 (en) Photoresist compositions with cyclic olefin polymers and additive
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain
GB2371600B (en) Device for the purpose of improving the injection sequence in fuel-injection systems
DE50002217D1 (de) Thyristoranordnung mit freiwerdeschutz